References
- Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010;376:1094-108. https://doi.org/10.1016/S0140-6736(10)60826-4
- Silman AJ and Pearson JE. Epidemiology and genetics of rheumatoid arthritis. Arthritis Res 2002;4(suppl):S265-72. https://doi.org/10.1186/ar578
- Hunter TM, Boytsov NN, Zhang X, et al. Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004-2014. Rheumatol Int 2017;37(9):1551-7. https://doi.org/10.1007/s00296-017-3726-1
- Minichiello E, Semerano L, Boissier MC. Time trends in the incidence, prevalence, and severity of rheumatoid arthritis: A systematic literature review. Joint Bone Spine 2016;83(6):625-30. https://doi.org/10.1016/j.jbspin.2016.07.007
- Naqvi AA, Hassali MA, Aftab MT. Epidemiology of rheumatoid arthritis, clinical aspects and socio-economic determinants in Pakistani patients: A systematic review and meta-analysis. J Pak Med Assoc 2019;69:389-98.
- Sandoo A, Chanchlani N, Hodson J, et al. Classical cardiovascular disease risk factors associate with vascular function and morphology in rheumatoid arthritis: a six-year prospective study. Arthritis Res Ther 2013;15:R203. doi:10.1186/ar4396 pmid:24289091
- Liao KP. Cardiovascular disease in patients with rheumatoid arthritis. Trends Cardiovasc Med 2017;27:136-40. https://doi.org/10.1016/j.tcm.2016.07.006
- England BR, Thiele GM, Anderson DR, et al. Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. BMJ 2018 Apr 23;361:k1036. doi: 10.1136/bmj.k1036
-
Arts EE, Fransen J, Den Broeder AA, et al. Low disease activity (DAS28
$\leq$ 3.2) reduces the risk of first cardiovascular event in rheumatoid arthritis: a time-dependent Cox regression analysis in a large cohort study. Ann Rheum Dis 2017;76:1693-9. doi: 10.1136/annrheumdis-2016-210997. - Solomon DH, Reed GW, Kremer JM, et al. Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheumatol 2015;67:1449-55. https://doi.org/10.1002/art.39098
- Ljung L, Rantapaa-Dahlqvist S, Jacobsson LT, et al. Response to biological treatment and subsequent risk of coronary events in rheumatoid arthritis. Ann Rheum Dis 2016;75:2087-94. https://doi.org/10.1136/annrheumdis-2015-208995
- Rempenault C, Combe B, Barnetche T, et al. Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2018;77(1):98-103. https://doi.org/10.1136/annrheumdis-2017-211836
- Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-84. https://doi.org/10.1002/art.23721
- Singh JA, Saag KG, Bridges SL, et al. 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2016;68(1):1-25. https://doi.org/10.1002/acr.22783
- Singh JA, Furst DE, Bharat A, et al. 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012;64:625-39. https://doi.org/10.1002/acr.21641
- Micha R, Imamura F, Wyler von Ballmoos M, et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 2011;108(9):1362-70. https://doi.org/10.1016/j.amjcard.2011.06.054
- O'Neill F, Charakida M, Topham E, et al. Anti-inflammatory treatment improves high-density lipoprotein function in rheumatoid arthritis. Heart 2017;103:766-73. https://doi.org/10.1136/heartjnl-2015-308953
- Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis 2017;76:17-28. https://doi.org/10.1136/annrheumdis-2016-209775
- Boo S, Oh H, Froelicher ES, et al. Knowledge and perception of cardiovascular disease risk among patients with rheumatoid arthritis. PLoS One 2017;12:e0176291 https://doi.org/10.1371/journal.pone.0176291
- Kim L, Kim JA, Kim S. A guide for the utilization of Health Insurance Review and Assessment Service National Patient Samples. Epidemiol Health 2014;36:e2014008.
- Robertson J, Peters MJ, McInnes IB, et al. Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nat Rev Rheumatol 2013;9:513-23. https://doi.org/10.1038/nrrheum.2013.91
- van Sijl AM, Peters MJ, Knol DL, et al. The effect of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: a metaanalysis. Semin Arthritis Rheum 2011;41:393-400. https://doi.org/10.1016/j.semarthrit.2011.04.003
- Choi HK, Hernan MA, Seeger JD, et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002;359:1173-7. https://doi.org/10.1016/S0140-6736(02)08213-2
- Greenberg JD, Kremer JM, Curtis JR, et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:576-82. https://doi.org/10.1136/ard.2010.129916
-
Barnabe C, Martin BJ, Ghali WA. Systematic review and metaanalysis: anti-tumor necrosis factor
${\alpha}$ therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2011;63:522-9. https://doi.org/10.1002/acr.20371 - Dierkes J and Westphal S. Effect of drugs on homocysteine concentrations. Semin Vasc Med 2005;5:124-39. https://doi.org/10.1055/s-2005-872398
- Merkle CJ, Moore IM, Penton BS, et al. Methotrexate causes apoptosis in postmitotic endothelial cells. Biol Res Nurs 2000;2:5-14. https://doi.org/10.1177/109980040000200102
- Lim DT, Cannella AC, Michaud KD, et al. Cardiovascular risk and the use of biologic agents in rheumatoid arthritis. Curr Rheumatol Rep 2014;16:459. https://doi.org/10.1007/s11926-014-0459-y
- Avina-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008;59:1690-7. https://doi.org/10.1002/art.24092
- Nicola PJ, Crowson CS, Maradit-Kremers H, et al. Contribution of congestive heart failure and ischemic heart disease to excess mortality in rheumatoid arthritis. Arthritis Rheum 2006;54:60-7. https://doi.org/10.1002/art.21560
- Schmidt TJ, Avina-Zubieta JA, Sayre EC, et al. Cardiovascular Disease Prevention in Rheumatoid Arthritis: Compliance with Diabetes Screening Guidelines. J Rheumatol 2018;45:1367-74. https://doi.org/10.3899/jrheum.170973
- Austin PC and Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med 2015;34(28):3661-79. https://doi.org/10.1002/sim.6607
- Glynn RJ, Schneeweiss S, Sturmer T. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol 2006;98(3):253-9. https://doi.org/10.1111/j.1742-7843.2006.pto_293.x
Cited by
- 지골피 추출물이 류마티스관절염 관련 매개체에 미치는 영향 vol.36, pp.4, 2019, https://doi.org/10.12925/jkocs.2019.36.4.1365
- Association of rheumatoid arthritis and high sodium intake with major adverse cardiovascular events: a cross-sectional study from the seventh Korean National Health and Nutrition Examination Survey vol.11, pp.12, 2019, https://doi.org/10.1136/bmjopen-2021-056255